Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib

Image: Puma Biotechnology has expanded two additional cohorts from the Phase II SUMMIT clinical trial investigating its lead drug candidate neratinib in patients with solid tumors. Photo: courtesy of renjith Krishnan / FreeDigitalPhotos.net.